Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States:: Results from the TRUST Surveillance Program (1998-2002)

被引:137
作者
Karlowsky, JA
Thornsberry, C
Jones, ME
Evangelista, AT
Critchley, IA
Sahm, DF
机构
[1] Focus Technol, Herndon, VA 20171 USA
[2] Focus Technol, Franklin, TN USA
[3] Focus Technol, Hilversum, Netherlands
[4] Ortho McNeil Pharmaceut, Raritan, NJ USA
关键词
D O I
10.1086/374052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To identify factors associated with antimicrobial resistance, data were analyzed from 27,828 isolates of Streptococcus pneumoniae submitted to the Tracking Resistance in the United States Today ( TRUST) surveillance program during 4 consecutive respiratory seasons. From the 1998-1999 season to the 2001-2002 season, the prevalence of azithromycin resistance increased by 4.8% to 27.5%, the prevalence of penicillin resistance increased by 3.7% to 18.4%, the prevalence of ceftriaxone resistance increased by 0.5% to 1.7%, and the prevalence of levofloxacin resistance increased by 0.3% to 0.9%. Isolates recovered from patients <18 years of age and lower respiratory tract specimens had elevated rates of penicillin, azithromycin, and trimethoprimsulfamethoxazole resistance (P<.00001); penicillin resistance correlated with coresistance to trimethoprimsulfamethoxazole (87.3%), azithromycin (76.3%), ceftriaxone ( 9.1%), and levofloxacin (1.3%) (P<.00001). Only 62 (0.2%) of 27,828 isolates were concurrently resistant to penicillin and levofloxacin. Minimum inhibitory concentrations (MICs) of penicillin correlated strongly with MICs of ceftriaxone (R-2=0.90), trimethoprimsulfamethoxazole (R-2=0.53), and azithromycin (R-2=0.41). Patient age, specimen source, and penicillin resistance were factors associated with antimicrobial resistance, particularly for nonfluoroquinolone antimicrobial agents.
引用
收藏
页码:963 / 970
页数:8
相关论文
共 29 条
[11]   Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Hoban, DJ ;
Doern, GV ;
Fluit, AC ;
Roussel-Delvallez, M ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S81-S93
[12]   Expanding uses of fluoroquinolones: Opportunities and challenges [J].
Hooper, DC .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (11) :908-910
[13]   Macrolide resistance among invasive Streptococcus pneumoniae isolates [J].
Hyde, TB ;
Gay, K ;
Stephens, DS ;
Vugia, DJ ;
Pass, M ;
Johnson, S ;
Barrett, NL ;
Schaffner, W ;
Cieslak, PR ;
Maupin, PS ;
Zell, ER ;
Jorgensen, JH ;
Facklam, RR ;
Whitney, CG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (15) :1857-1862
[14]   Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters:: 1997 US surveillance study [J].
Jacobs, MR ;
Bajaksouzian, S ;
Zilles, A ;
Lin, GR ;
Pankuch, GA ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1901-1908
[15]   Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season [J].
Jones, ME ;
Sahm, DF ;
Martin, N ;
Scheuring, S ;
Heisig, P ;
Thornsberry, C ;
Köhrer, K ;
Schmitz, FJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :462-466
[16]   Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model [J].
Klepser, ME ;
Ernst, EJ ;
Petzold, CR ;
Rhomberg, P ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :673-678
[17]  
Liñares J, 1999, NEW ENGL J MED, V341, P1546
[18]  
[NCCLS] National Committee for Clinical Laboratory Standards, 2002, M100S12 NCCLS
[19]  
NCCLS - NATIONAL Committee for Clinical Laboratory Standards, 1997, M7A4 NCCLS
[20]   Guidelines for the management of adults with community-acquired pneumonia - Diagnosis, assessment of severity, antimicrobial therapy, and prevention [J].
Niederman, MS ;
Mandell, LA ;
Anzueto, A ;
Bass, JB ;
Broughton, WA ;
Campbell, GD ;
Dean, N ;
File, T ;
Fine, MJ ;
Gross, PA ;
Martinez, F ;
Marrie, TJ ;
Plouffe, JF ;
Ramirez, J ;
Sarosi, GA ;
Torres, A ;
Wilson, R ;
Yu, VL .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (07) :1730-1754